161 related articles for article (PubMed ID: 31248366)
1. Healthcare use by 30,000 patients with irritable bowel syndrome (IBS) in France: a 5-year retrospective and one-year prospective national observational study.
Sabaté JM; Rivière S; Jouet P; Gastaldi-Menager C; Fagot-Campagna A; Tuppin P
BMC Gastroenterol; 2019 Jun; 19(1):111. PubMed ID: 31248366
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries.
Tack J; Stanghellini V; Mearin F; Yiannakou Y; Layer P; Coffin B; Simren M; Mackinnon J; Wiseman G; Marciniak A;
BMC Gastroenterol; 2019 May; 19(1):69. PubMed ID: 31064345
[TBL] [Abstract][Full Text] [Related]
4. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
5. [Irritable bowel syndrome and healthcare consumption. An observational study in private gastroenterology].
Dapoigny M; Dyard F; Grimaud JC; Guyot P; van Ganse E
Gastroenterol Clin Biol; 2003 Mar; 27(3 Pt 1):265-71. PubMed ID: 12700510
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of coeliac disease in patients fulfilling Rome III criteria for irritable bowel syndrome.
Shalaby SA; Sayed MM; Ibrahim WA; Abdelhakam SM; Rushdy M
Arab J Gastroenterol; 2016 Jun; 17(2):73-7. PubMed ID: 27349575
[TBL] [Abstract][Full Text] [Related]
7. Predictors of healthcare-seeking behavior among Chinese patients with irritable bowel syndrome.
Fan WJ; Xu D; Chang M; Zhu LM; Fei GJ; Li XQ; Fang XC
World J Gastroenterol; 2017 Nov; 23(42):7635-7643. PubMed ID: 29204063
[TBL] [Abstract][Full Text] [Related]
8. A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain.
Mearin F; Caballero AM; Serra J; Brotons C; Tantiñà A; Fort E; Martínez-Cerezo FJ; Perelló A; Sánchez-Antolín G; Rey E; Angós Musgo R; Berdier R; Gómez-Rodríguez B; Clavé P; García-Alonso M; Torán-Monserrat P; Tack J
Gastroenterol Hepatol; 2019 Mar; 42(3):141-149. PubMed ID: 30612850
[TBL] [Abstract][Full Text] [Related]
9. Racial disparity in healthcare utilization among patients with Irritable Bowel Syndrome: results from a multicenter cohort.
Silvernale C; Kuo B; Staller K
Neurogastroenterol Motil; 2021 May; 33(5):e14039. PubMed ID: 33263195
[TBL] [Abstract][Full Text] [Related]
10. Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study.
Brun-Strang C; Dapoigny M; Lafuma A; Wainsten JP; Fagnani F
Eur J Gastroenterol Hepatol; 2007 Dec; 19(12):1097-103. PubMed ID: 17998835
[TBL] [Abstract][Full Text] [Related]
11. An excess of prior irritable bowel syndrome diagnoses or treatments in Celiac disease: evidence of diagnostic delay.
Card TR; Siffledeen J; West J; Fleming KM
Scand J Gastroenterol; 2013 Jul; 48(7):801-7. PubMed ID: 23697749
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of irritable bowel syndrome in China.
Zhang F; Xiang W; Li CY; Li SC
World J Gastroenterol; 2016 Dec; 22(47):10450-10460. PubMed ID: 28058026
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Med Econ; 2017 Apr; 20(4):353-362. PubMed ID: 27919177
[TBL] [Abstract][Full Text] [Related]
14. IBS clinical management in Italy: The AIGO survey.
Soncini M; Stasi C; Usai Satta P; Milazzo G; Bianco M; Leandro G; Montalbano LM; Muscatiello N; Monica F; Galeazzi F; Bellini M;
Dig Liver Dis; 2019 Jun; 51(6):782-789. PubMed ID: 30448159
[TBL] [Abstract][Full Text] [Related]
15. Perceived risk as a barrier to appropriate diagnosis of irritable bowel syndrome.
Ahn E; Son KY; Shin DW; Han MK; Lee H; An AR; Kim EH; Cho B
World J Gastroenterol; 2014 Dec; 20(48):18360-6. PubMed ID: 25561803
[TBL] [Abstract][Full Text] [Related]
16. Therapist telephone-delivered CBT and web-based CBT compared with treatment as usual in refractory irritable bowel syndrome: the ACTIB three-arm RCT.
Everitt H; Landau S; Little P; Bishop FL; O'Reilly G; Sibelli A; Holland R; Hughes S; Windgassen S; McCrone P; Goldsmith K; Coleman N; Logan R; Chalder T; Moss-Morris R
Health Technol Assess; 2019 Apr; 23(17):1-154. PubMed ID: 31042143
[TBL] [Abstract][Full Text] [Related]
17. [Irritable bowel syndrome in the Russian Federation: results of the ROMERUS multicenter observational study].
Maev IV; Okhlobystina OZ; Khalif IL; Andreev DN
Ter Arkh; 2023 Feb; 95(1):38-51. PubMed ID: 37167114
[TBL] [Abstract][Full Text] [Related]
18. Healthcare Utilization Patterns: Irritable Bowel Syndrome, Inflammatory Bowel Disease, and Gastroesophageal Reflux Disease.
Koloski N; Shah A; Kaan I; Ben Jacob R; Talley NJ; Jones MP; Holtmann G
Dig Dis Sci; 2024 May; 69(5):1626-1635. PubMed ID: 38400884
[TBL] [Abstract][Full Text] [Related]
19. Healthcare spending and utilization for pediatric Irritable Bowel Syndrome in a commercially insured population.
Beinvogl B; Palmer N; Kohane I; Nurko S
Neurogastroenterol Motil; 2021 Nov; 33(11):e14147. PubMed ID: 33818857
[TBL] [Abstract][Full Text] [Related]
20. Functional dyspepsia leads to more healthcare utilization in secondary care compared with other functional gastrointestinal disorders.
Chuah KH; Cheong SY; Lim SZ; Mahadeva S
J Dig Dis; 2022 Feb; 23(2):111-117. PubMed ID: 35050547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
